Immunosuppressive Therapies Adversely Affect Blood Biochemical Parameters in Patients with Inflammatory Bowel Disease: a Meta-analysis

Overview

Journal J Int Med Res

Publisher Sage Publications

Specialty General Medicine

Date 2019 Aug 1

PMID 31364448

Citations 1

Authors

Xiaobing Wang

Ge Wang

Jian Shang

Huaqin Pan

Xin A Zhang

Feng Zhou

Affiliations

Soon will be listed here.

Citing Articles

Machine Learning Prediction Model for Inflammatory Bowel Disease Based on Laboratory Markers. Working Model in a Discovery Cohort Study.

Kraszewski S, Szczurek W, Szymczak J, Regula M, Neubauer K J Clin Med. 2021; 10(20).

PMID: 34682868 PMC: 8539616. DOI: 10.3390/jcm10204745.

References

Arora S, Katkov W, Cooley J, Kemp J, Johnston D, Schapiro R . Methotrexate in Crohn's disease: results of a randomized, double-blind, placebo-controlled trial. Hepatogastroenterology. 1999; 46(27):1724-9. View

Sood A, Midha V, Sood N, Kaushal V . Role of azathioprine in severe ulcerative colitis: one-year, placebo-controlled, randomized trial. Indian J Gastroenterol. 2000; 19(1):14-6. View

Feagan B, Fedorak R, Irvine E, Wild G, Sutherland L, Steinhart A . A comparison of methotrexate with placebo for the maintenance of remission in Crohn's disease. North American Crohn's Study Group Investigators. N Engl J Med. 2000; 342(22):1627-32. DOI: 10.1056/NEJM200006013422202. View

ROSENBERG J, Levin B, Wall A, Kirsner J . A controlled trial of azathioprine in Crohn's disease. Am J Dig Dis. 1975; 20(8):721-6. DOI: 10.1007/BF01070829. View

Hermida C, Moreno-Otero R . 6-mercaptopurine or methotrexate added to prednisone induces and maintains remission in steroid-dependent inflammatory bowel disease. Eur J Gastroenterol Hepatol. 2000; 12(11):1227-33. DOI: 10.1097/00042737-200012110-00010. View

Egan L, Tremaine W, Mays D, Lipsky J, Sandborn W . Clinical outcome and pharmacokinetics after addition of low-dose cyclosporine to methotrexate: a case study of five patients with treatment-resistant inflammatory bowel disease. Inflamm Bowel Dis. 2001; 6(4):286-9. DOI: 10.1002/ibd.3780060406. View

Sood A, Kaushal V, Midha V, Bhatia K, Sood N, Malhotra V . The beneficial effect of azathioprine on maintenance of remission in severe ulcerative colitis. J Gastroenterol. 2002; 37(4):270-4. DOI: 10.1007/s005350200034. View

Bernal I, Domenech E, Garcia-Planella E, Cabre E, Gassull M . [Opportunistic infections in patients with inflammatory bowel disease undergoing immunosuppressive therapy]. Gastroenterol Hepatol. 2003; 26(1):19-22. DOI: 10.1016/s0210-5705(03)70335-5. View

Alfadhli A, McDonald J, Feagan B . Methotrexate for induction of remission in refractory Crohn's disease. Cochrane Database Syst Rev. 2003; (1):CD003459. DOI: 10.1002/14651858.CD003459. View

10.

Sandborn W, Present D, Isaacs K, Wolf D, Greenberg E, Hanauer S . Tacrolimus for the treatment of fistulas in patients with Crohn's disease: a randomized, placebo-controlled trial. Gastroenterology. 2003; 125(2):380-8. DOI: 10.1016/s0016-5085(03)00877-1. View

11.

Lennard L . The clinical pharmacology of 6-mercaptopurine. Eur J Clin Pharmacol. 1992; 43(4):329-39. DOI: 10.1007/BF02220605. View

12.

Vilien M, Dahlerup J, Munck L, Norregaard P, Gronbaek K, Fallingborg J . Randomized controlled azathioprine withdrawal after more than two years treatment in Crohn's disease: increased relapse rate the following year. Aliment Pharmacol Ther. 2004; 19(11):1147-52. DOI: 10.1111/j.1365-2036.2004.01944.x. View

13.

Su C, Lichtenstein G . Treatment of inflammatory bowel disease with azathioprine and 6-mercaptopurine. Gastroenterol Clin North Am. 2004; 33(2):209-34, viii. DOI: 10.1016/j.gtc.2004.02.004. View

14.

Lemann M, Mary J, Colombel J, Duclos B, Soule J, Lerebours E . A randomized, double-blind, controlled withdrawal trial in Crohn's disease patients in long-term remission on azathioprine. Gastroenterology. 2005; 128(7):1812-8. DOI: 10.1053/j.gastro.2005.03.031. View

15.

Kandiel A, Fraser A, Korelitz B, Brensinger C, Lewis J . Increased risk of lymphoma among inflammatory bowel disease patients treated with azathioprine and 6-mercaptopurine. Gut. 2005; 54(8):1121-5. PMC: 1774897. DOI: 10.1136/gut.2004.049460. View

16.

Hawthorne A, Logan R, Hawkey C, Foster P, Axon A, Swarbrick E . Randomised controlled trial of azathioprine withdrawal in ulcerative colitis. BMJ. 1992; 305(6844):20-2. PMC: 1882467. DOI: 10.1136/bmj.305.6844.20. View

17.

Lichtenstein G, Abreu M, Cohen R, Tremaine W . American Gastroenterological Association Institute technical review on corticosteroids, immunomodulators, and infliximab in inflammatory bowel disease. Gastroenterology. 2006; 130(3):940-87. DOI: 10.1053/j.gastro.2006.01.048. View

18.

Sternthal M, Murphy S, George J, Kornbluth A, Lichtiger S, Present D . Adverse events associated with the use of cyclosporine in patients with inflammatory bowel disease. Am J Gastroenterol. 2008; 103(4):937-43. DOI: 10.1111/j.1572-0241.2007.01718.x. View

19.

Toruner M, Loftus Jr E, Harmsen W, Zinsmeister A, Orenstein R, Sandborn W . Risk factors for opportunistic infections in patients with inflammatory bowel disease. Gastroenterology. 2008; 134(4):929-36. DOI: 10.1053/j.gastro.2008.01.012. View

20.

Sahasranaman S, Howard D, Roy S . Clinical pharmacology and pharmacogenetics of thiopurines. Eur J Clin Pharmacol. 2008; 64(8):753-67. DOI: 10.1007/s00228-008-0478-6. View